Home›Margetuximab Cmkb›Margetuximab Cmkb + Tetracycline

Does Margetuximab Cmkb Interact with Tetracycline?

Margetuximab Cmkb and Tetracycline have a major drug interaction according to U.S. FDA drug labeling data. Patients receiving anthracyclines less than 4 months after stopping MARGENZA may be at increased risk of cardiac dysfunction. Avoid anthracycline-based therapy for up to 4 months after stopping MARGENZA. The mechanism involves increased risk of cardiac dysfunction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Margetuximab Cmkb Class
HER2/neu Receptor Antagonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Margetuximab Cmkb and Tetracycline occurs because increased risk of cardiac dysfunction. Clinically, this means patients receiving anthracyclines less than 4 months after stopping margenza may be at increased risk of cardiac dysfunction. avoid anthracycline-based therapy for up to 4 months after stopping margenza. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Margetuximab Cmkb and your doctor is considering prescribing Tetracycline (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Margetuximab Cmkb(Margenza)+💊 Tetracycline

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
HER2/neu Receptor Antagonist
Drug B class
—
Source
NLP:margetuximab-cmkb

What this means in plain English

Patients receiving anthracyclines less than 4 months after stopping MARGENZA may be at increased risk of cardiac dysfunction. Avoid anthracycline-based therapy for up to 4 months after stopping MARGENZA.

What the FDA label says

"Increased risk of cardiac dysfunction"

📖 Source: NLP:margetuximab-cmkb

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Margetuximab Cmkb and Tetracycline against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.